報價延遲最少15分鐘:2026/04/25 17:04 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
5.425 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-129.10/-187.84
|
|
企業價值
2.88M
|
| 資產負債 |
|
每股賬面淨值
11.07
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
838.14K
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Decoy Therapeutics Inc is a pre-clinical stage biotechnology company focused on advancing its pipeline of peptide conjugate therapeutics engineered through its proprietary IMP3ACT platform. The IMP3ACT platform represents a paradigm shift in peptide conjugate drug discovery and manufacturing, leveraging machine learning (ML) and artificial intelligence (AI" tools alongside high-speed synthesis techniques to rapidly engineer, optimize and manufacture peptide conjugates that target serious unmet medical needs. The company manages its business in one operating segment, focused on the discovery and development therapeutics for patients with high, unmet medical needs. Its pipeline programs include: Pan-Coronavirus;and Tripledemic. |
